FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2969494549> ?p ?o ?g. }

• W2969494549 endingPage "5902" @default.
• W2969494549 startingPage "5891" @default.
• W2969494549 abstract "This open-label, phase I dose-finding study evaluated the gonadotropin-releasing hormone antagonist, TAK-385, in Japanese patients with nonmetastatic prostate cancer. In a two-part design, patients received daily oral TAK-385 at doses of 320 (loading, day 1)/80 (maintenance, day 2 and thereafter), 320/120, 320/160, or 360/120 mg for 28 days in a dose-escalation phase (part A, n = 13), and at 320/80 or 320/120 mg for up to 96 weeks in a randomized expansion phase (part B, n = 30). Primary endpoint in both parts was safety, including dose-limiting toxicity in part A. Secondary endpoints included pharmacokinetics, pharmacodynamics, and prostate-specific antigen concentration. Ten (77%) patients in part A and all patients in part B experienced an adverse event; hot flush (part A, n = 4; part B, n = 15), viral upper respiratory tract infection (part A, n = 1; part B, n = 10), and diarrhea (part B, n = 8) were most frequent. No dose-limiting toxicities were observed (part A). In 12 evaluable patients (part A), TAK-385 was rapidly absorbed after a single loading dose; on day 28 (maintenance dose), median steady-state Tmax was ~1-2 hours and mean t1/2z was 67-79 hours. All doses rapidly reduced testosterone concentrations to castration levels within 1 week. Durable reductions in prostate-specific antigen of >90% from baseline were observed through 96 weeks. TAK-385 appeared tolerable and resulted in sustained reductions in testosterone to castration levels at all doses. The lowest loading/maintenance dose required for a clinical effect was 320/80 mg. ClinicalTrials.gov: NCT02141659." @default.
• W2969494549 created "2019-08-29" @default.
• W2969494549 creator A5011250166 @default.
• W2969494549 creator A5020294120 @default.
• W2969494549 creator A5024866909 @default.
• W2969494549 creator A5035879888 @default.
• W2969494549 creator A5036460015 @default.
• W2969494549 creator A5039958599 @default.
• W2969494549 creator A5046362015 @default.
• W2969494549 creator A5056993350 @default.
• W2969494549 creator A5060006109 @default.
• W2969494549 creator A5081210650 @default.
• W2969494549 creator A5085955274 @default.
• W2969494549 date "2019-08-19" @default.
• W2969494549 modified "2023-10-17" @default.
• W2969494549 title "Phase I trial of TAK‐385 in hormone treatment‐naïve Japanese patients with nonmetastatic prostate cancer" @default.
• W2969494549 cites W114049227 @default.
• W2969494549 cites W1546725983 @default.
• W2969494549 cites W1720362365 @default.
• W2969494549 cites W1878336561 @default.
• W2969494549 cites W189198258 @default.
• W2969494549 cites W1979937973 @default.
• W2969494549 cites W1982014262 @default.
• W2969494549 cites W1986472546 @default.
• W2969494549 cites W1994894880 @default.
• W2969494549 cites W2008203144 @default.
• W2969494549 cites W2011996781 @default.
• W2969494549 cites W2016927496 @default.
• W2969494549 cites W2045981419 @default.
• W2969494549 cites W2049161486 @default.
• W2969494549 cites W2084467580 @default.
• W2969494549 cites W2118586907 @default.
• W2969494549 cites W2138323789 @default.
• W2969494549 cites W2324382147 @default.
• W2969494549 cites W2550373105 @default.
• W2969494549 cites W2554033186 @default.
• W2969494549 cites W2587863482 @default.
• W2969494549 cites W2590061441 @default.
• W2969494549 cites W2725924624 @default.
• W2969494549 cites W2760987813 @default.
• W2969494549 cites W2795707114 @default.
• W2969494549 cites W2969494549 @default.
• W2969494549 doi "https://doi.org/10.1002/cam4.2442" @default.
• W2969494549 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6792482" @default.
• W2969494549 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31429205" @default.
• W2969494549 hasPublicationYear "2019" @default.
• W2969494549 type Work @default.
• W2969494549 sameAs 2969494549 @default.
• W2969494549 citedByCount "21" @default.
• W2969494549 countsByYear W29694945492019 @default.
• W2969494549 countsByYear W29694945492020 @default.
• W2969494549 countsByYear W29694945492021 @default.
• W2969494549 countsByYear W29694945492022 @default.
• W2969494549 countsByYear W29694945492023 @default.
• W2969494549 crossrefType "journal-article" @default.
• W2969494549 hasAuthorship W2969494549A5011250166 @default.
• W2969494549 hasAuthorship W2969494549A5020294120 @default.
• W2969494549 hasAuthorship W2969494549A5024866909 @default.
• W2969494549 hasAuthorship W2969494549A5035879888 @default.
• W2969494549 hasAuthorship W2969494549A5036460015 @default.
• W2969494549 hasAuthorship W2969494549A5039958599 @default.
• W2969494549 hasAuthorship W2969494549A5046362015 @default.
• W2969494549 hasAuthorship W2969494549A5056993350 @default.
• W2969494549 hasAuthorship W2969494549A5060006109 @default.
• W2969494549 hasAuthorship W2969494549A5081210650 @default.
• W2969494549 hasAuthorship W2969494549A5085955274 @default.
• W2969494549 hasBestOaLocation W29694945491 @default.
• W2969494549 hasConcept C111113717 @default.
• W2969494549 hasConcept C112705442 @default.
• W2969494549 hasConcept C121608353 @default.
• W2969494549 hasConcept C126322002 @default.
• W2969494549 hasConcept C126894567 @default.
• W2969494549 hasConcept C168563851 @default.
• W2969494549 hasConcept C197934379 @default.
• W2969494549 hasConcept C203092338 @default.
• W2969494549 hasConcept C2779256933 @default.
• W2969494549 hasConcept C2779279991 @default.
• W2969494549 hasConcept C2780192828 @default.
• W2969494549 hasConcept C2781406297 @default.
• W2969494549 hasConcept C29730261 @default.
• W2969494549 hasConcept C71315377 @default.
• W2969494549 hasConcept C71924100 @default.
• W2969494549 hasConcept C90924648 @default.
• W2969494549 hasConceptScore W2969494549C111113717 @default.
• W2969494549 hasConceptScore W2969494549C112705442 @default.
• W2969494549 hasConceptScore W2969494549C121608353 @default.
• W2969494549 hasConceptScore W2969494549C126322002 @default.
• W2969494549 hasConceptScore W2969494549C126894567 @default.
• W2969494549 hasConceptScore W2969494549C168563851 @default.
• W2969494549 hasConceptScore W2969494549C197934379 @default.
• W2969494549 hasConceptScore W2969494549C203092338 @default.
• W2969494549 hasConceptScore W2969494549C2779256933 @default.
• W2969494549 hasConceptScore W2969494549C2779279991 @default.
• W2969494549 hasConceptScore W2969494549C2780192828 @default.
• W2969494549 hasConceptScore W2969494549C2781406297 @default.
• W2969494549 hasConceptScore W2969494549C29730261 @default.
• W2969494549 hasConceptScore W2969494549C71315377 @default.
• W2969494549 hasConceptScore W2969494549C71924100 @default.

• next